A new study reveals that ensifentrine, a novel COPD treatment, significantly reduces COPD-related healthcare usage over 48 ...

Discover the latest insights from the TOReTO study on COPD management: Dual bronchodilator therapy has been shown to reduce exacerbations, with varying efficacy between current and former smokers.

Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3Through October more than 2,200 unique ...

Q3 2024 Earnings Conference Call November 4, 2024 9:00 AM ETCompany ParticipantsDavid Zaccardelli - President and ...

Chronic Obstructive Pulmonary Disease (COPD): For those with COPD ... Immediate treatments include using short-acting ...

After Diwali celebrations, the air quality in Gurgaon has significantly deteriorated, leading to a sharp rise in respiratory ...

Global Dyspnea Treatment MarketThe global dyspnea treatment market, valued at USD 5.90 billion in 2022, is expected to experience robust growth, projected to reach approximately USD 12.3 billion by ...

Discontinuing medical treatment can trigger asthma attacks, so regular check-ups are essential for managing the condition.

If advised by a healthcare provider, bronchodilators, which help in keeping the airways open, can make breathing easier ...

As reported by the Central Pollution Control Board's SAMEER app, Mumbai's Air Quality Index (AQI) on Sunday was 157, which ...

Ohtuvayre™ (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti ...